

## References – Age Related Macular Degeneration: Pearls for Primary Care

1. Klein R, Klein BEK, Knudtson MD, et al. Fifteen -Year Cumulative Incidence of Age-Related Macular Degeneration, The Beaver Dam Eye Study. *Ophthalmology* 2007;114:253-262.
2. Ambati J, Ambati B, Yoa SH, et al. Age-Related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies. *Surv Ophthalmol* 2003;48(3):257-293.
3. Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss, AREDS Report No. 8. *Arch Ophthalmol* 2001;119:1417-1436.
4. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers. *N Engl J Med* 1994;330:1029-1035.
5. Michaelsson K, Lithell H, Vessby B, et al. Serum Retinol Levels and the Risk of Fracture. *N Engl J Med* 2003;348:287-294.
6. Anastasopoulos E, Yu F, Coleman AL. Age-Related Macular Degeneration is Associated With an Increased Risk of Hip Fractures in the Medicare Database. *Am J Ophthalmol* 2006;142:1081-1083.
7. Khan JC, Thurby DA, Shahid H, et al. Smoking and Age Related Macular Degeneration: The Number of Pack Years of Cigarette Smoking is a Major Determinant of Risk for Both Geographic Atrophy and Choroidal Neovascularization. *Br J Ophthalmol* 2006;90:75-80.
8. Age-Related Eye Disease Study Group. Risk Factors Associated With Macular Degeneration. A Case-Control Study in the Age-Related Eye Disease Study. Age-Related Eye Disease Study Report Number 3. *Ophthalmology* 2000;107:2224-2232.
9. Seddon JM, Rosner B, Sperduto RD, et al. Dietary Fat: The Risk for Advanced Age-Related Macular Degeneration. *Arch Ophthalmol* 2001;119:1191-1199.
10. Seddon JM, Cote J, Davis N, et al. Progression of Age-Related Macular Degeneration: Association with Body Mass Index, Waist Circumference, and Waist-Hip Ratio. *Arch Ophthalmol* 2003;121:785-792.
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. *N Engl J Med* 2006;355:1420.
12. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration. *N Engl J Med* 2006;355:1432-1444.

13. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration. *Ophthalmology* 2007;114:246-252.
14. Steinbrook R. The Price of Sight. Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration. *N Engl J Med* 2006;355:1409-1412.
15. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-Term Safety and Efficacy of Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration. *Retina* 2006;26:495-511.
16. Avery R, Pieramici DJ, Rabena MD, et al. Intravitreal Bevacizumab ( Avastin) for Neovascular Age-Related Macular Degeneration. *Ophthalmology* 2006;113:363-372.
17. Bashur ZF, Bazarabachi A, Schahal A, et al. Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-Related Macular Degeneration. *Am J Ophthalmol* 2006;142:1-9.
18. Open letter from Genentech regarding subgroup analysis in the SAILOR clinical trial. Jan 2007.